Ocular Therapeutix (OCUL) Net Margin (2014 - 2026)

Ocular Therapeutix's Net Margin history runs 13 years deep, the most recent figure standing at 835.11% for Q1 2026.

• In Q1 2026, Net Margin fell 24552.0% year-over-year to 835.11%; the TTM figure through Mar 2026 stood at 558.22% (down 22894.0% YoY), while the FY2025 annual figure was 507.2%, down 24815.0% from the prior year.
• Net Margin was 835.11% for Q1 2026 at Ocular Therapeutix, down from 492.45% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 142.09% in Q3 2023 to a low of 835.11% in Q1 2026.
• Historically, Net Margin has averaged 305.69% across 5 years, with a median of 214.88% in 2024.
• The sharpest annual moves came in 2022 and 2025: Net Margin surged 15036 bps in 2022, then sank 37472 bps in 2025.
• A 5-year view of Net Margin shows it stood at 147.67% in 2022, then declined by 4 bps to 153.65% in 2023, then plunged by 87 bps to 286.92% in 2024, then tumbled by 72 bps to 492.45% in 2025, then slumped by 70 bps to 835.11% in 2026.
• The last three Net Margin figures came in at 835.11% (Q1 2026), 492.45% (Q4 2025), and 467.35% (Q3 2025), per Business Quant data.